AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Revenue of AbCellera Biologics Inc. (ABCL)
Revenue in 2023 (TTM): $38.03 M
According to AbCellera Biologics Inc.'s latest financial reports the company's current revenue (TTM) is $38.03 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of AbCellera Biologics Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $38.03 M | $38.03 M | $-192,158,000 | $-174,029,000 | $-146,398,000 |
| 2022 | $485.42 M | $418.99 M | $272.2 M | $239.1 M | $158.52 M |
| 2021 | $375.2 M | $329.69 M | $241.62 M | $219.15 M | $153.46 M |
| 2020 | $233.16 M | $206.01 M | $169.62 M | $157.83 M | $118.92 M |
| 2019 | $11.61 M | $1.5 M | $-397,417 | $-2,210,696 | $-2,419,892 |
| 2018 | $8.83 M | $3.03 M | $165 K | $309 K | $309 K |